Skip to main content
. 2022 Dec 13;13:1051353. doi: 10.3389/fimmu.2022.1051353

Figure 2.

Figure 2

Serum concentration of B2M, IGFBP3, and IGFALS in different stages of ALD patients. (A) Serum concentration of B2M in HC group, non-severe ALD group, and severe ALD group. (B) Serum concentration of IGFBP3 in HC group, non-severe ALD group, and severe ALD group. (C) Serum concentration of IGFALS in HC group, non-severe ALD group, and severe ALD group. ns is P>0.05; * P<0.05; ****P<0.0001.